Home › Research › TREM2 and immune genetics
Reformulating Pro-Oxidant Microglia in Neurodegeneration
García-Revilla J, Alonso-Bellido IM, Burguillos MA, Herrera AJ, Espinosa-Oliva AM, Ruiz R, Cruz-Hernández L, García-Domínguez I et al.. Journal of clinical medicine, 2019-10-17
Topic: Brain proteins, microglia and lab models
In neurodegenerative diseases, microglia-mediated neuroinflammation and oxidative stress are central events. Recent genome-wide transcriptomic analyses of microglial cells under different disease conditions have uncovered a new subpopulation named disease-associated microglia (DAM). These studies have challenged the classical view of the microglia polarization state's proinflammatory M1 (classical activation) and immunosuppressive M2 (alternative activation).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
García-Revilla, J., Alonso-Bellido, I. M., Burguillos, M. A., Herrera, A. J., Espinosa-Oliva, A. M., Ruiz, R., et al. (2019). Reformulating Pro-Oxidant Microglia in Neurodegeneration. Journal of clinical medicine. https://doi.org/10.3390/jcm8101719
Vancouver
García-Revilla J, Alonso-Bellido IM, Burguillos MA, Herrera AJ, Espinosa-Oliva AM, Ruiz R, et al. Reformulating Pro-Oxidant Microglia in Neurodegeneration. Journal of clinical medicine. 2019. doi:10.3390/jcm8101719. PMID: 31627485.
BibTeX
@article{garciarevilla2019-31627485,
author = {García-Revilla, J. and Alonso-Bellido, I. M. and Burguillos, M. A. and Herrera, A. J. and Espinosa-Oliva, A. M. and Ruiz, R. and Cruz-Hernández, L. and García-Domínguez, I. and others},
title = {{Reformulating Pro-Oxidant Microglia in Neurodegeneration}},
journal = {Journal of clinical medicine},
year = {2019},
doi = {10.3390/jcm8101719},
pmid = {31627485},
url = {https://doi.org/10.3390/jcm8101719}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Recent genome-wide transcriptomic analyses of microglial cells under different disease conditions have uncovered a new subpopulation named disease-associated microglia (DAM).
- These studies have challenged the classical view of the microglia polarization state's proinflammatory M1 (classical activation) and immunosuppressive M2 (alternative activation).
- Molecular signatures of DAM and proinflammatory microglia (highly pro-oxidant) have shown clear differences, yet a partial overlapping gene profile is evident between both phenotypes.
- The switch activation of homeostatic microglia into reactive microglia relies on the selective activation of key surface receptors involved in the maintenance of brain homeostasis (a.k.a. pattern recognition receptors, PRRs).
Why it matters
This review discusses disease-associated microglia and pro-oxidant microglia in neurodegeneration, challenging the classical M1/M2 polarization view. It is a conceptual review and does not report a treatment or cure.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of clinical medicine) |
| Journal's citation record | 2 / 4 | Journal of Clinical Medicine: journal h-index 188 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 62 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.9 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 3 / 6 | Cited 4.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jose Luis Venero: h-index 49 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidad de Sevilla: institution h-index 520 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31627485) |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3390/jcm8101719
- PubMed: 31627485
- Original source →
- Free full text: Journal of Clinical Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 34.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics
Also tagged “vessel”
900 studies in the library carry the topic tag “vessel”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.